

**NAMSDL**



**National Alliance for Model State Drug Laws**

**TABLE OF CATHINONES AND  
CATHINONE DERIVATIVES  
BILLS, STATUTES & REGULATIONS**

© 2011 Research is current as of February 25, 2011. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or [hgray@namsdl.org](mailto:hgray@namsdl.org) with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

The following table illustrates what the states are doing with regard to scheduling cathinones and cathinone derivatives and, where indicated, which states have already scheduled the substances by statute (S) or regulation (R).

	<u>cathinone</u> <sup>1</sup>	<u>methcathinone</u> <sup>2</sup>	<u>mephedrone</u> <sup>3</sup>	<u>methedrone</u> <sup>4</sup>	<u>Flephedrone</u> <sup>5</sup>	<u>3-FMC</u> <sup>6</sup>	<u>methylone</u> <sup>7</sup>	<u>MDPV</u> <sup>8</sup>
Alabama	X(R)	X(R)						
Alaska		X(S)						
Arizona	X(S)	X(S)						
Arkansas	X(R)	X(R)	X	X	X	X	X	X
California	X(S)							
Colorado	X(S)	X(S)						
Connecticut	X(R)	X(R)						
Delaware	X(S)	X(S)						

<sup>1</sup> 2-amino-1-phenyl propanone

<sup>2</sup> 2-methylamino-1-phenylpropan-1-one

<sup>3</sup> 4-methylmethcathinone; 4-MMC; 4-methylephedrone; (RS)-2-methylamino-1-(4-methylphenyl)propan-1-one

<sup>4</sup> Bk-PMMA; para-methoxymethcathinone; 4-methoxymethcathinone; PMMC; methoxyphedrine; (RS)-1-(4-methoxyphenyl)-2-(methylamino)propan-1-one

<sup>5</sup> 4-fluoromethcathinone

<sup>6</sup> 3-fluoromethcathinone

<sup>7</sup> 3,4-methylenedioxy-N-methylcathinone; bk-MDMA; MDMC

<sup>8</sup> Methylenedioxypyrovalerone; MDPK; 3,4-methylenedioxypyrovalerone

© 2011 Research is current as of February 25, 2011. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

District of Columbia	X(S)							
Florida <sup>9</sup>	X(S)	X(S)	X(R)		X(R)	X(R)	X(R)	X(R)
Georgia	X(S)	X(S)	X	X	X		X	X
Hawaii	X(S)	X(S)	X					X
Idaho	X(S)	X(S)						
Illinois	X(S)	X(S)						X
Indiana	X(S)	X(S)						
Iowa	X(S)	X(S)	X <sup>10</sup>					X
Kansas <sup>11</sup>	X(S)	X(S)						
Kentucky	X(R)	X(S)	X				X	X
Louisiana <sup>12</sup>	X(S)	X(S)	X(R)	X(R)	X(R)	X(R)	X(R)	X(R)

<sup>9</sup> Florida scheduled mephedrone, 4-fluoromethcathinone, 3-fluoromethcathinone, methylone and MDPV by rule on an emergency basis on January 26, 2011. 2ER11-1.

<sup>10</sup> Iowa is proposing to schedule (RS)-2-methylamino-1-(4-methylphenyl)propan-1-one, a/k/a 4-MMC, as "mephedrine."

<sup>11</sup> Kansas is proposing to add a version of the ACMD generic language.

<sup>12</sup> Louisiana scheduled mephedrone, methedrone, 4-fluoromethcathinone, 3-fluoromethcathinone, methylone, and MDPV by regulation on an emergency basis on January 20, 2011. 2011 Reg. Text 247982.

Maine								
Maryland			X	X	X	X	X	X
Massachusetts								
Michigan	X(S)	X(S)	X <sup>13</sup>					
Minnesota	X(S)	X(S)						
Mississippi	X(S)	X(S)	X					X
Missouri	X(S)	X(S)						X
Montana	X(S)	X(S)						
Nebraska	X(S)	X(S)						
Nevada	X(R)	X(R)						
New Hampshire <sup>14</sup>	X(R)	X(R)						
New Jersey								

<sup>13</sup> Michigan schedules 4-methylmethcathinone as “mephadone” under M.C.L.A. §333.7212.

<sup>14</sup> New Hampshire references the federal code, 21 USC 801, et seq., for its list of scheduled substances.

© 2011 Research is current as of February 25, 2011. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

New Mexico <sup>15</sup>	X(R)	X(R)	X		X	X	X	X
New York <sup>16</sup>	X(S)	X(S)	X	X	X	X	X	X
North Carolina	X(S)	X(S)	X					X
North Dakota	X(S)	X(S)	X(R) <sup>17</sup>					X(R)
Ohio	X(S)	X(S)						
Oklahoma		X(S)	X	X	X	X	X	X
Oregon	X(R)	X(R)						
Pennsylvania	X(R)	X(R)	X	X	X	X	X	X
Rhode Island			X	X <sup>18</sup>	X <sup>19</sup>	X	X	X
South Carolina								
South Dakota	X(S)	X(S)						

<sup>15</sup> New Mexico is proposing to schedule 3-methoxymethcathinone which may be methedrone.

<sup>16</sup> New York is proposing to add the ACMD generic language.

<sup>17</sup> North Dakota also has a proposed bill, 2011 ND S.B. 2119, that would schedule mephedrone by statute.

<sup>18</sup> Rhode Island is proposing to schedule “methoxymethcathinone” generally.

<sup>19</sup> Rhode Island is proposing to schedule “fluoromethcathinone” generally.

© 2011 Research is current as of February 25, 2011. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

Tennessee <sup>20</sup>	X(R)	X(R) (S)	X	X	X	X	X	X
Texas	X(S)	X(S)						
Utah	X(S)	X(S)	X	X	X	X	X	X
Vermont		X(R)						
Virginia	X(S)	X(S)						
Washington	X(S)	X(S)						
West Virginia	X(S)	X(S)	X <sup>21</sup>					X
Wisconsin	X(S)	X(S)						
Wyoming	X(S)	X(S)	X	X	X	X	X	X

(S) = Substance is scheduled by statute

(R) = Substance is scheduled or proposed to be scheduled by regulation

<sup>20</sup> Tennessee schedules methcathinone by both statute and regulation. Tenn. Code Ann. §39-17-406 classifies methcathinone and *Catha edulis* as Schedule I drugs when cathinone is present, and *Catha edulis* as a Schedule IV drug (TCA §39-17-412) when cathinone is absent but cathine is present. TN ADC 0940-06-01-.01 schedules both cathinone and methcathinone as Schedule I substances.

<sup>21</sup> West Virginia seeks to add mephedrone to its list of alternate names for methcathinone.